Breaking News

Lonza, BioWa License Cell Line Technology to MedImmune

To use Potelligent CHOK1SV in pipeline of multiple antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioWa, Inc. and Lonza have entered an agreement with MedImmune to license the Potelligent CHOK1SV Cell Line Technology for use in multiple proprietary antibodies in MedImmune’s pipeline.   Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent Technology with Lonza’s GS Gene Expression System, which includes Lonza’s host cell line, CHOK1SV. Potelligent Technology is designed to improve the potency and efficacy o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters